Stemtech

Stemtech EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Stemtech (STEK) as of Nov 3, 2026 is 13.60 %. In the previous year, EBIT CAGR (5 Year) was 13.60 % — a change of 0.00% (lower).

EBIT CAGR 5Y

13.60 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Stemtech is 2025 13.60 % . EBIT CAGR (5 Year) of Stemtech was 2024 13.60 % . It decreases by 0.00% lower compared to the previous year.

The Stemtech EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2018
13.60 USD
Jan 1, 2019
13.60 USD
Jan 1, 2020
13.60 USD
Jan 1, 2021
13.60 USD
Jan 1, 2022
13.60 USD
Jan 1, 2023
13.60 USD
Jan 1, 2024
13.60 USD
Jan 1, 2025
13.60 USD
The Stemtech EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %0.00%
13.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stemtech Stock analysis

What does Stemtech do? Stemtech Corp develops nutritional supplements that support stem cell activity, marketed internationally through subsidiaries and independent distributors. The company's products include the RCM System, stemrelease3, Stemflo MigraStem, OraStem for oral health, and D-Fuze for electromagnetic frequency blocking. Cellect One Rapid Renew Stem Cell Peptide Night Cream is its skincare offering. Products are sold in North America, Latin America, and Asia through distributors and subsidiaries. The firm's brands target health-conscious consumers seeking stem cell support, with OraStem focusing on oral care and D-Fuze addressing electromagnetic frequency concerns. Independent distributors handle sales across all segments, leveraging the company's international presence. The RCM System and stemrelease3 are core products for general stem cell enhancement. Stemtech Corp's revenue streams come from direct sales of its branded nutritional supplements and skincare products. Distributors purchase products from subsidiaries to resell, generating consistent income through these channels. The company's international segments ensure diverse market coverage without relying on a single region. Stemtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemtech stock

EBIT CAGR (5 Year) of Stemtech is 13.60 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Stemtech since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Stemtech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Stemtech

All Key Metrics — Stemtech